Provider of an in vivo drug discovery platform and AI models. The company uses a mosaic in vivo drug discovery platform and next-generation AI models for in vivo data generation, and single-cell precision, to capture in vivo context of disease and to represent patient diversity in drug response over current in vitro assays. The company was founded in 2022 and headquartered in San Francisco, United States. It has raised $12M in seed funding, with backing from Wing Venture Capital, General Catalyst, Mubadala, AIX Ventures, and others. The company operates in the High Tech - Generative AI, Native AI - Generative AI, HealthTech - Life Sciences Tech space.
← All startups
Vevo Therapeutics
SeedProvider of an in vivo drug discovery platform and AI models. The company uses a mosaic in vivo drug discovery platform and next-generation AI models for in vivo data generation, and single-cell precision, to capture in vivo context of disease and to represent patient diversity in drug response over current in vitro assays. The company was founded in 2022 and headquartered in San Francisco, United States. It has…
About
Business model
Life Sciences Tech > Research & Development > Drug Informatics
Institutional investors
Wing Venture CapitalGeneral CatalystMubadalaAIX VenturesCamford Capital
Latest coverage
📰 Browse funding news — rounds, valuations, and market moves for founders.
Investor directory
🗂️ See who's investing in High Tech — full fund directory with check size and geography.